Intercept Pharmaceuticals, Inc.
ICPT · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $418 | $519 | $814 | $3,923 |
| - Cash | $51 | $85 | $58 | $70 |
| + Debt | $333 | $547 | $576 | $539 |
| Enterprise Value | $701 | $981 | $1,332 | $4,391 |
| Revenue | $286 | $363 | $313 | $252 |
| % Growth | -21.4% | 16.2% | 24.1% | – |
| Gross Profit | $285 | $360 | $307 | $248 |
| % Margin | 99.7% | 99.1% | 98.3% | 98.3% |
| EBITDA | -$62 | -$35 | -$212 | -$295 |
| % Margin | -21.6% | -9.6% | -67.9% | -116.9% |
| Net Income | $115 | -$145 | -$324 | -$391 |
| % Margin | 40.3% | -39.9% | -103.7% | -155.2% |
| EPS Diluted | 3.4 | -4.55 | -9.83 | -12.35 |
| % Growth | 174.7% | 53.7% | 20.4% | – |
| Operating Cash Flow | -$27 | -$42 | -$170 | -$237 |
| Capital Expenditures | -$1 | -$0 | -$4 | -$1 |
| Free Cash Flow | -$27 | -$42 | -$174 | -$238 |